CVM
Price
$2.10
Change
-$0.26 (-11.02%)
Updated
May 30 closing price
Capitalization
6.58M
MDGL
Price
$275.26
Change
+$5.33 (+1.97%)
Updated
May 30 closing price
Capitalization
6.11B
66 days until earnings call
Interact to see
Advertisement

CVM vs MDGL

Header iconCVM vs MDGL Comparison
Open Charts CVM vs MDGLBanner chart's image
Cel-Sci
Price$2.10
Change-$0.26 (-11.02%)
Volume$430.78K
Capitalization6.58M
Madrigal Pharmaceuticals
Price$275.26
Change+$5.33 (+1.97%)
Volume$326.94K
Capitalization6.11B
CVM vs MDGL Comparison Chart
Loading...
CVM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CVM vs. MDGL commentary
Jun 01, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CVM is a Buy and MDGL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 01, 2025
Stock price -- (CVM: $2.10 vs. MDGL: $275.26)
Brand notoriety: CVM: Notable vs. MDGL: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CVM: 295% vs. MDGL: 94%
Market capitalization -- CVM: $6.58M vs. MDGL: $6.11B
CVM [@Biotechnology] is valued at $6.58M. MDGL’s [@Biotechnology] market capitalization is $6.11B. The market cap for tickers in the [@Biotechnology] industry ranges from $303.58B to $0. The average market capitalization across the [@Biotechnology] industry is $2.22B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CVM’s FA Score shows that 0 FA rating(s) are green whileMDGL’s FA Score has 0 green FA rating(s).

  • CVM’s FA Score: 0 green, 5 red.
  • MDGL’s FA Score: 0 green, 5 red.
According to our system of comparison, MDGL is a better buy in the long-term than CVM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CVM’s TA Score shows that 4 TA indicator(s) are bullish while MDGL’s TA Score has 4 bullish TA indicator(s).

  • CVM’s TA Score: 4 bullish, 6 bearish.
  • MDGL’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, MDGL is a better buy in the short-term than CVM.

Price Growth

CVM (@Biotechnology) experienced а -16.33% price change this week, while MDGL (@Biotechnology) price change was +2.88% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.39%. For the same industry, the average monthly price growth was +0.48%, and the average quarterly price growth was -5.03%.

Reported Earning Dates

CVM is expected to report earnings on May 15, 2025.

MDGL is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+1.39% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MDGL($6.11B) has a higher market cap than CVM($6.58M). MDGL YTD gains are higher at: -10.795 vs. CVM (-82.496). CVM has higher annual earnings (EBITDA): -21.96M vs. MDGL (-376.15M). CVM has less debt than MDGL: CVM (11.1M) vs MDGL (120M). MDGL has higher revenues than CVM: MDGL (317M) vs CVM (0).
CVMMDGLCVM / MDGL
Capitalization6.58M6.11B0%
EBITDA-21.96M-376.15M6%
Gain YTD-82.496-10.795764%
P/E RatioN/AN/A-
Revenue0317M-
Total CashN/A843M-
Total Debt11.1M120M9%
FUNDAMENTALS RATINGS
CVM vs MDGL: Fundamental Ratings
CVM
MDGL
OUTLOOK RATING
1..100
5151
VALUATION
overvalued / fair valued / undervalued
1..100
98
Overvalued
63
Fair valued
PROFIT vs RISK RATING
1..100
10041
SMR RATING
1..100
9894
PRICE GROWTH RATING
1..100
9963
P/E GROWTH RATING
1..100
55100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MDGL's Valuation (63) in the Pharmaceuticals Other industry is somewhat better than the same rating for CVM (98) in the Biotechnology industry. This means that MDGL’s stock grew somewhat faster than CVM’s over the last 12 months.

MDGL's Profit vs Risk Rating (41) in the Pharmaceuticals Other industry is somewhat better than the same rating for CVM (100) in the Biotechnology industry. This means that MDGL’s stock grew somewhat faster than CVM’s over the last 12 months.

MDGL's SMR Rating (94) in the Pharmaceuticals Other industry is in the same range as CVM (98) in the Biotechnology industry. This means that MDGL’s stock grew similarly to CVM’s over the last 12 months.

MDGL's Price Growth Rating (63) in the Pharmaceuticals Other industry is somewhat better than the same rating for CVM (99) in the Biotechnology industry. This means that MDGL’s stock grew somewhat faster than CVM’s over the last 12 months.

CVM's P/E Growth Rating (55) in the Biotechnology industry is somewhat better than the same rating for MDGL (100) in the Pharmaceuticals Other industry. This means that CVM’s stock grew somewhat faster than MDGL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CVMMDGL
RSI
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
73%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
71%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
80%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
75%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
75%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 19 days ago
81%
Bullish Trend 24 days ago
77%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 3 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
80%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
77%
View a ticker or compare two or three
Interact to see
Advertisement
CVM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
VUSE60.630.34
+0.57%
Vident U.S. Equity Strategy ETF
NANC39.26N/A
N/A
Unusual Whales Subversive Dem Trd ETF
EBIZ29.77-0.11
-0.37%
Global X E-commerce ETF
ADIV16.59-0.09
-0.54%
SmartETFs Asia Pcfc Dvdnd Bldr ETF
EPI46.26-0.27
-0.58%
WisdomTree India Earnings ETF